Product1 distinct publisher3 min readPublished
The FDA-authorized sensor gives Type 1 patients a continuous warning for the emergency most adult clinicians never send test strips home for, using the same ketone reading that any low-carb dieter would happily buy.
The Product Desk · Product desk
Compiled by The Product DeskSomething wrong?How this is made
The column that reported the authorization opens in 2004, with its author vomiting into a plastic bag in the back of a Honda Odyssey after two days of it, a teenager who was not diabetic and whose unsupervised low-carb diet had pushed the ketones in her blood to toxic levels; she was diagnosed by peeing on a strip of paper and watching it change colour [13].
The analyte itself does not care about the diagnosis. For a Type 1 patient, the mechanism behind Taub's check engine light is specific: without enough insulin to turn glucose into energy, the liver burns fat instead, and the ketones that come off it can acidify the blood fast enough to be fatal [3][6][7]. For someone whose insulin works, a climbing beta-hydroxybutyrate line is what a low-carb diet is for. That is the same sensor reading, with the arrow pointing in the direction the user was hoping for.
Victoria Song, writing the Verge's Optimizer column, asks whether the Duo can avoid the wearable hype cycle [2]. The reason that question does real work here is that Abbott's clinical case rests entirely on people who cannot make insulin, while nothing in the reading itself limits the audience to them.
A launch like this invites a simple framing: continuous monitoring replacing intermittent testing. Ahn's account of adult practice says that framing misses the point [11], since the real change is not sampling frequency but whether any ketone data exists in the house at all.
Then the packaging. Both readings come off one patch, worn ten days [4], so unbroken coverage works out to 365 divided by 10, roughly 36.5 sensors a year [14], and the ketone alarm is available exactly as often as the glucose alarm [15]. Anyone stretching sensors to save money loses the emergency warning in the same motion as the routine one.
What the column does not offer is any figure for alert burden: how many additional alarms the ketone channel raises, or what caregivers who now receive two kinds of alert do with the second [16].
So the forcing function for a clinic, a payer, or an employer wellness program has two axes. Can the user's body still make insulin, and is there a written action for a high ketone reading with a named person to take it. Insulin-deficient with an action: the sensor does the job, and the insulin pump users Ahn flags are the cleanest version of it [12]. Insulin-deficient without one: an alarm that lands before anyone has decided what it means. Insulin-sufficient with an action: rare, mostly research. Insulin-sufficient without one: a metabolic scoreboard, which is a reasonable thing to want and a poor thing to fund out of a diabetes budget. The number reported is identical in all four boxes, and the obligation to act on it is the entire product.
Ranked by verification strength, evidence, and original report placement.
Abbott obtained FDA authorization for a new continuous glucose monitor, the Libre Duo, described as the first 2-in-1 CGM that measures both glucose and ketone levels.
The Verge's Optimizer column, written by senior reviewer Victoria Song, reported the authorization and asked whether the 2-in-1 CGM can avoid the wearable hype cycle.
According to Mark Taub, vice president of technical operations for Abbott's diabetes care business, the new sensor measures beta-hydroxybutyrate, a type of ketone, and is intended to function like a "check engine light".
The sensor is worn for 10 days at a time and can deliver alerts both when a diabetic's glucose levels are out of range and when ketones rise.
The sensor uses the same app as Abbott's existing CGM, works with smartwatches, and allows caregivers to monitor the glucose and ketone levels of loved ones, which the column notes matters because DKA is a significant risk among diabetic children.
Diabetic ketoacidosis occurs when there is not enough insulin to turn blood glucose into energy, so the liver burns fat and produces ketones as a byproduct; too many ketones make the blood highly acidic, a process that can be alarmingly fast in diabetics and fatal if left untreated.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · September 2, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
The self-driving lab is out. Whether AI shows up in your filing is still open.1 distinct publisher
product
Hochul defends a Meta teen settlement whose age checks land on every adult account1 distinct publisher
build
The FCC read HOVERAir's Versa by what it was built to do, not how it was boxed2 distinct publishers
product
Google's new Preferred Sources button hands publishers the recruiting job2 distinct publishers
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Mechanics from the maker, stakes from a clinician
Every specification here — beta-hydroxybutyrate as the analyte, 10-day wear, paired alerts, app continuity — traces to one Abbott executive, and The Verge quotes no authorization letter, accuracy study, or price to check him against. What keeps this above launch-day stenography is Dr. David Ahn, who has nothing riding on the product and supplies the two most falsifiable facts in the piece: that adult clinicians rarely prescribe ketone strips, and that SGLT2 inhibitors break the high-blood-sugar clue clinicians use to catch DKA.
Cleared, not counted
An authorization is permission to sell, and that is all this reporting establishes. No ship date, no price, no payer decision, no prescriber or patient numbers appear anywhere. The nearest thing to a demand signal points the wrong way: Ahn's observation that most adult clinicians do not bother sending home inexpensive ketone strips describes a habit the Duo would have to create, not one it inherits.
A step ahead of what's shown
The column earns credit for asking the hype question in its own subhead and for letting a clinician complicate the pitch. But the two loudest lines in it are Abbott's and neither is checked: "first 2-in-1" and "leading cause of hospitalization." A check-engine light is a generous metaphor for a warning system whose false-alarm rate nobody has published, and the caregiver-monitoring benefit is asserted rather than demonstrated.
The vendor supplies the technical witness
Abbott is announcing its own device and is the only voice describing how it works, which is the ordinary launch arrangement and should be read as one. There is a second, quieter pull: a ketone reading is commercially interesting to every low-carb dieter with a phone, and this is a consumer-gadget newsletter. Pushing back are two honest counterweights — Song's near-fatal teenage ketoacidosis, which is hers rather than anyone's talking point, and Ahn's flat statement that clinicians like him do not bother with ketone strips.
One column, two voices, one of them selling
This rests on a single publisher and a single piece, with exactly two named sources. The hardware facts are the kind that a regulatory filing would confirm and are unlikely to be wrong. The "first ever" designation and the hospitalization statistics would not stand on this basis alone, and the entire commercial picture — price, coverage, availability — is absent rather than uncertain.